Comparable stake leader
Janus Henderson Group Ltd.
SEC ownership of Monopar Therapeutics
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001645469.
Disclosed value leader
Janus Henderson Group Ltd.
Comparable rows
26/41
Latest evidence
30 Jun 2026
- Public ticker
- MNPR on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Janus Henderson Group Ltd.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
26 of 41
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Janus Henderson Group Ltd.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001645469
- Issuer location
- Wilmette, IL
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Monopar Therapeutics (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
Janus Henderson Group Ltd.
Comparable rows
26/41
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 20%
15 rows are not safely comparable across share classes.
13D/G row: Janus Henderson Group Ltd.
Showing 1-8 of 41 holder rows.
Quick read
Janus Henderson Group Ltd. leads the comparable SEC ownership view at 20%.
26 of 41 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership
Top 5
Janus Henderson Group Ltd.
20%
RA CAPITAL MANAGEMENT, L.P.
9.9%
ASTRAZENECA PLC
7.8%
Adage Capital Management, L.P.
6.2%
Saturn V Capital Management LP
5.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 41 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
20%
|
$105,138,701
1,287,368 shares
|
+$9,391,992 | 30 Sep 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
9.9%
|
$43,402,756
667,632 shares
|
-$4,890,637 | 31 Dec 2025 |
| ASTRAZENECA PLC |
13D/G
|
7.8%
|
$34,126,392
522,667 shares
|
$0 | 31 Dec 2025 |
| Adage Capital Management, L.P. |
13D/G
|
6.2%
|
$23,788,856
424,195 shares
|
-$9,814,000 | 31 Mar 2026 |
| Saturn V Capital Management LP |
13D/G
|
5.2%
|
$19,382,706
345,626 shares
|
$0 | 05 Jan 2026 |
| Hendricks Diane |
3/4/5
10%+ Owner
|
8.5%
|
$50,213,802
567,580 shares
|
— | 16 Dec 2025 |
| Tactic Pharma LLC |
3/4/5
10%+ Owner
|
4.1%
|
$17,303,519
272,026 shares
|
-$34,999,957 | 24 Sep 2025 |
| BlackRock, Inc. |
13F
Company
|
5.2%
|
$32,297,151
348,819 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$35,238,921.
Buys
$104,925
Insiders: 1
Sells
$35,343,846
Insiders: 2
Net
-$35,238,921
Shares: -553,850
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 1,500
Shares: 555,350
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 1,500 | 5,121 | $104,925 | $343,889 | -$238,964 |
| 9-12 | 0 | 550,229 | $0 | $34,999,957 | -$34,999,957 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to Monopar Therapeutics. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Largest Forms 3/4/5 holder
Hendricks Diane
Net 12M change
-$35,238,921
Latest report
30 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Hendricks Diane | 10%+ Owner | $50,213,802 | Mixed | 16 Dec 2025 | ||
| Tactic Pharma LLC | 10%+ Owner | $17,303,519 | -$34,999,957 | -67% | Filing P/S | 24 Sep 2025 |
| Chandler Robinson | Chief Executive Officer, Director | $12,327,369 | Mixed | 30 Jun 2026 | ||
| Andrew Cittadine | Chief Operating Officer | $4,183,501 | Mixed | 30 Jun 2026 | ||
| Arthur J. Klausner | Director | $596,604 | -$343,889 | -37% | Filing P/S | 18 Dec 2025 |
| Christopher M. Starr | Director | $538,894 | Mixed | 02 Dec 2025 | ||
| Kim R. Tsuchimoto | Director | $459,453 | Filing P/S | 02 Dec 2025 | ||
| Lavina Talukdar | Director | $308,022 | Mixed | 02 Dec 2025 | ||
| Michael J. Brown | Director | $136,941 | Mixed | 31 Dec 2023 | ||
| Quan Anh Vu | Chief Financial Officer | $121,688 | +$104,925 | +626% | Mixed | 30 Jun 2026 |
| Andrew Paul Mazar | Chief Scientific Officer, Director | $94,434 | Mixed | 31 Mar 2022 | ||
| Karthik Radhakrishnan | Chief Financial Officer | $10,447 | Mixed | 28 Oct 2024 | ||
| TacticGem LLC | 10%+ Owner | $0 | Mixed | 09 Dec 2024 | ||
| Raymond Anderson | Director | Mixed | 02 Dec 2025 | |||
| Jose Octavio Pinto Costa Filho | Chief Medical Officer | Mixed | 12 Jul 2021 | |||
| Susan Rodriguez | Ccso | Mixed | 02 Mar 2026 | |||
| Patrice Rioux | Acting Chief Medical Officer | Mixed | 01 Jan 2026 | |||
| Nicole Sweeny | Director | Mixed | 26 Jun 2026 |
Recent insider transactions for Monopar Therapeutics
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Quan Anh Vu | MNPR | Common Stock | Tax liability | -18.6% | -507 | 2,221 | 30 Jun 2026 | Direct | ||
| Quan Anh Vu | MNPR | Common Stock | Options Exercise | 81.9% | 1,228 | 2,728 | 30 Jun 2026 | Direct | ||
| Quan Anh Vu | MNPR | Restricted Stock Unit | Options Exercise | -12.5% | -1,228 | 8,598 | 30 Jun 2026 | Direct | ||
| Chandler Robinson | MNPR | Common Stock | Tax liability | -3.95% | -4,084 | 99,267 | 30 Jun 2026 | Direct | ||
| Chandler Robinson | MNPR | Common Stock | Options Exercise | 14.2% | 12,873 | 103,351 | 30 Jun 2026 | Direct | ||
| Chandler Robinson | MNPR | Restricted Stock Unit | Options Exercise | -12.1% | -12,873 | 93,403 | 30 Jun 2026 | Direct | ||
| Andrew Cittadine | MNPR | Common Stock | Tax liability | -3.99% | -2,309 | 55,614 | 30 Jun 2026 | Direct | ||
| Andrew Cittadine | MNPR | Common Stock | Options Exercise | 9.98% | 5,254 | 57,923 | 30 Jun 2026 | Direct | ||
| Andrew Cittadine | MNPR | Restricted Stock Unit | Options Exercise | -11.7% | -5,254 | 39,499 | 30 Jun 2026 | Direct | ||
| Nicole Sweeny | MNPR | Stock Options | Award | 1,284 | 1,284 | 26 Jun 2026 | Direct | |||
| Chandler Robinson | MNPR | Common Stock | Tax liability | -2.13% | -1,972 | 90,478 | 31 Mar 2026 | Direct | ||
| Chandler Robinson | MNPR | Common Stock | Options Exercise | 7.85% | 6,732 | 92,450 | 31 Mar 2026 | Direct | ||
| Chandler Robinson | MNPR | Restricted Stock Unit | Options Exercise | -5.96% | -6,732 | 106,276 | 31 Mar 2026 | Direct | ||
| Andrew Cittadine | MNPR | Common Stock | Tax liability | -2.9% | -1,571 | 52,669 | 31 Mar 2026 | Direct | ||
| Andrew Cittadine | MNPR | Common Stock | Options Exercise | 6.93% | 3,514 | 54,240 | 31 Mar 2026 | Direct | ||
| Andrew Cittadine | MNPR | Restricted Stock Unit | Options Exercise | -7.28% | -3,514 | 44,753 | 31 Mar 2026 | Direct | ||
| Susan Rodriguez | MNPR | Stock Options | Award | 48,728 | 48,728 | 02 Mar 2026 | Direct | |||
| Patrice Rioux | MNPR | Stock Option | Award | 2,000 | 2,000 | 01 Jan 2026 | Direct | |||
| Chandler Robinson | MNPR | Common Stock | Tax liability | -2.9% | -2,558 | 85,718 | 31 Dec 2025 | Direct | ||
| Chandler Robinson | MNPR | Common Stock | Options Exercise | 11% | 8,724 | 88,276 | 31 Dec 2025 | Direct | ||
| Chandler Robinson | MNPR | Restricted Stock Unit | Options Exercise | -7.17% | -8,724 | 113,008 | 31 Dec 2025 | Direct | ||
| Andrew Cittadine | MNPR | Common Stock | Tax liability | -3.59% | -1,889 | 50,726 | 31 Dec 2025 | Direct | ||
| Andrew Cittadine | MNPR | Common Stock | Options Exercise | 8.96% | 4,326 | 52,615 | 31 Dec 2025 | Direct | ||
| Andrew Cittadine | MNPR | Restricted Stock Unit | Options Exercise | -8.23% | -4,326 | 48,267 | 31 Dec 2025 | Direct | ||
| Quan Anh Vu | MNPR | Common Stock | Purchase | $104,925 | $69.95 | 1,500 | 1,500 | 26 Dec 2025 | Direct | |
| Arthur J. Klausner | MNPR | Common Stock | Sale | -36.9% | $343,889 | $67.15 | -5,121 | 8,762 | 18 Dec 2025 | Direct |
| Diane Hendricks | MNPR | Common Stock | Other | -7.12% | -43,499 | 567,580 | 16 Dec 2025 | See footnote | ||
| Arthur J. Klausner | MNPR | Common Stock | Other | 124.9% | 7,710 | 13,883 | 16 Dec 2025 | Direct | ||
| Andrew Cittadine | MNPR | Restricted Stock Units | Award | 36% | 13,919 | 52,593 | 02 Dec 2025 | Direct | ||
| Andrew Cittadine | MNPR | Stock Options | Award | 8,969 | 8,969 | 02 Dec 2025 | Direct | |||
| Christopher M. Starr | MNPR | Stock Options | Award | 2,924 | 2,924 | 02 Dec 2025 | Direct | |||
| Arthur J. Klausner | MNPR | Stock Options | Award | 2,924 | 2,924 | 02 Dec 2025 | Direct | |||
| Raymond Anderson | MNPR | Stock Options | Award | 2,924 | 2,924 | 02 Dec 2025 | Direct | |||
| Lavina Talukdar | MNPR | Stock Options | Award | 2,924 | 2,924 | 02 Dec 2025 | Direct | |||
| Kim R. Tsuchimoto | MNPR | Stock Options | Award | 2,924 | 2,924 | 02 Dec 2025 | Direct | |||
| Quan Anh Vu | MNPR | Restricted Stock Units | Award | 9,826 | 9,826 | 02 Dec 2025 | Direct | |||
| Quan Anh Vu | MNPR | Stock Options | Award | 7,135 | 7,135 | 02 Dec 2025 | Direct | |||
| Chandler Robinson | MNPR | Restricted Stock Units | Award | 67.7% | 49,133 | 121,732 | 02 Dec 2025 | Direct | ||
| Chandler Robinson | MNPR | Stock Options | Award | 16,753 | 16,753 | 02 Dec 2025 | Direct | |||
| Andrew Cittadine | MNPR | Common Stock | Tax liability | -3.78% | -1,896 | 48,289 | 30 Sep 2025 | Direct | ||
| Andrew Cittadine | MNPR | Common Stock | Options Exercise | 9.44% | 4,327 | 50,185 | 30 Sep 2025 | Direct | ||
| Andrew Cittadine | MNPR | Restricted Stock Units | Options Exercise | -10.1% | -4,327 | 38,674 | 30 Sep 2025 | Direct | ||
| Chandler Robinson | MNPR | Common Stock | Tax liability | -3.22% | -2,646 | 79,552 | 30 Sep 2025 | Direct | ||
| Chandler Robinson | MNPR | Common Stock | Options Exercise | 11.9% | 8,726 | 82,198 | 30 Sep 2025 | Direct | ||
| Chandler Robinson | MNPR | Restricted Stock Units | Options Exercise | -10.7% | -8,726 | 72,599 | 30 Sep 2025 | Direct | ||
| Tactic Pharma LLC | MNPR | Common Stock | Sale | -66.9% | $34,999,957 | $63.61 | -550,229 | 272,026 | 24 Sep 2025 | Direct |
* marks a reported price that did not pass the local price check.